AMENDMENT OF THE CLAIMS:

1. (Currently amended) A compound of formula (I):

wherein:

R¹ represents is substituted or unsubstituted heteroaryl;

Y represents is $-(CR_{na}R_{nb})_n$ -;

R_{na} and R_{nb} are each independently hydrogen or C₁₋₆alkyl;

n is an integer from 0 to 5;

R² represents is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;

R³ and R⁴ each independently represent are hydrogen or C₁₋₆alkyl;

R⁷ represents is hydrogen or C₁₋₆alkyl;

R⁸ represents is hydrogen or C₁₋₆alkyl;

and salts and solvates thereof;

with the proviso that the following compounds are excluded;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(pyridin-3-ylmethyl)urea;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(6-methoxypyridin-3-yl)methyl]urea;

5-({[({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)carbonyl]-amino}methyl)nicotinamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(1H-indol-5-ylmethyl)urea;

 $N-\{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}-N'-(1H-indol-4-ylmethyl)urea;\\$

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(5-methylisoxazol-3-yl)methyl]urea;

 $N-\{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}-N'-(thien-2-ylmethyl)urea;$

 $N-\{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}-N'-(2-thien-2-ylethyl)urea;$

```
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-({5-[(dimethylamino)methyl]--2-furyl}methyl)urea;
```

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(3-methoxyisothiazol-5-yl)methyl]urea;

 $N-\{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}-N'-[(4-methyl-1,3-thiazol-2-yl)methyl]urea; \\$

 $N-\{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}-N'-(1,3-thiazol-2-ylmethyl)urea;\\$

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(2-methyl-1,3-thiazol-4-yl)methyl]urea;

methyl 2-({[({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)carbonyl]-amino}-methyl)--4-methyl-1,3-thiazole-5-carboxylate;

N-[(5-amino-1-phenyl-1H-pyrazol-4-yl)methyl]-N'-{[4-(3,4-dichlorobenzyl)-morpholin-2-yl]methyl}urea;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)urea;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-({5-[(dimethylamino)-methyl]thien-2-yl}methyl)urea;

.N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(2-furylmethyl)urea;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(2-methyl-2H-tetraazol-5-yl)methyl]urea;

 $N-\{[3-(4-chlorophenyl)isoxazol-5-yl]methyl\}-N'-\{[(2S)-4-(3,4-dichlorobenzyl)-morpholin-2-yl]methyl\}urea;$

N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(2-methyl-2H-tetraazol-5-yl)methyl]urea;

 $N-\{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}-N'-[(4-methyl-1,3-thiazol-2-yl)methyl]urea;$

N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(1,3-thiazol-2-ylmethyl)-urea, and;

 $N-\{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}-N'-\{[3-(4-methoxyphenyl)-isoxazol-5-yl]methyl\}urea.$

2. (Original) A compound of formula (I) according to claim 1 wherein R¹ is 3-formamido-1,2,4-triazol-5-yl, 5-trifluoromethyl-1,3,4-oxadiazol-2-yl, 5-(morpholin-4-ylmethyl)-1,3,4-oxadiazol-2-yl, 5-(N,N-diethylaminomethyl)-1,3,4-oxadiazol-2-yl, 5-

ethylaminomethyl-1,3,4-oxadiazol-2-yl, furan-2-yl, 4-(3-methyl-1,2,4-oxadiazol-5yl)furan-2-yl, 4-(3-methyl-1,2,4-triazol-5-yl)furan-2-yl, 4-(5-methyl-1,3,4-oxadiazol-2-yl)furan-2-yl, imidazol-2-yl, 1-methylimidazol-5-yl, imidazol-4-yl, 3-(cyclopropylmethylaminocarbonyl)isoxazol-5-yl, 3-(N-pyrrolidinecarbonyl)isoxazol-5-yl, 4-methoxycarbonyloxazol-2-yl, 4-ethylaminocarbonyloxazol-2-yl, 4cyclopropylmethylaminocarbonyloxazol-2-yl, 4-methylaminocarbonyloxazol-2-yl, 4-(N-pyrrolidinecarbonyl)oxazol-2-yl, 4-iso-propylaminocarbonyloxazol-2-yl, 1methylcarbonylpyrazol-3-yl, pyridin-4-yl, pyridin-2-yl, pyridin-3-yl, 5aminocarbonylpyridin-3-yl, 4-aminopyrimidin-5-yl, 4-hydroxy-2-methylpyrimidin-5yl, 1-methyltetrazol-5-yl, 2-methoxycarbonylmethyltetrazol-5-yl, 1methoxycarbonylmethyltetrazol-5-yl, 2-cyclopropylmethyltetrazol-5-yl, 1cyclopropylmethyltetrazol-5-yl, 2-ethyltetrazol-5-yl, 1-ethyltetrazol-5-yl, 2-tertbutyltetrazol-5-yl, 5-trifluoromethyltetrazol-2-yl, 2-cyanomethyltetrazol-5-yl, 1cyanomethyltetrazol-5-yl, 2-iso-butyltetrazol-5-yl, 1-iso-butyltetrazol-5-yl, 4-(isopropylaminocarbonyl)thiophen-2-yl, 4-(methylaminocarbonyl)thiophen-2-yl, 4-(ethylaminocarbonyl)thiophen-2-yl, 2-(iso-propyl)tetrazol-5-yl, 1,2,3-triazol-4-yl, 1methyl-1,2,3-triazol-4-yl, 2-methyl-1,2,3-triazol-4-yl, 1-methyl-1,2,4-triazol-3-yl, 5methyl-1,2,4-oxadiazol-3-yl, 3-ethoxycarbonyl-1,2,4-oxadiazol-5-yl, 3methylaminocarbonyl-1,2,4-oxadiazol-5-yl, 3-ethylaminocarbonyl-1,2,4-oxadiazol-5yl, 5-(5-methylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl, 5-methylaminocarbonyl-1,2,4oxadiazol-3-yl, 2-methyl-1,3,4-oxadiazol-5-yl, pyrazin-2-yl, 3-methylisoxazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 3-(pyrrolidine-N-carbonyl)-1,2,4oxadiazol-5-yl, 3-(iso-propylaminocarbonyl)-1,2,4-oxadiazol-5-yl, 5-(ethylaminocarbonyl)-1,2,4-oxadiazol-3-yl, 3-(cyclopropylaminocarbonyl)-1,2,4oxadiazol-5-yl, 3-(iso-propyl(methyl)aminocarbonyl)-1,2,4-oxadiazol-5-yl, 1-isopropyltetrazol-5-yl, tetrazol-5-yl, 3-amino-1,2,4-triazol-5-yl, 5-methylisoxazol-3-yl, 1-methylpyrazol-4-yl, 2-methylaminocarbonyl-1,3,4-oxadiazol-5-yl, 2ethylaminocarbonyl-1,3,4-oxadiazol-5-yl, 2-(iso-propylaminocarbonyl)-1,3,4oxadiazol-5-yl, 2-carboxyfuran-5-yl, 2-(ethoxycarbonyl)furan-5-yl, 2-(methylaminocarbonyl)furan-5-yl, 2-(ethylaminocarbonyl)furan-5-yl, 2-(isopropylaminocarbonyl)furan-5-yl, 1-methylpyrazol-3-yl, pyrazol-3-yl, 3methylpyrazol-5-yl, 3-(ethoxycarbonyl)isoxazol-5-yl, 2-methyltetrazol-5-yl, 3-(methylaminocarbonyl)furan-5-yl, 3-(ethylaminocarbonyl)furan-5-yl, 3-(isopropylaminocarbonyl)furan-5-yl, 3-(methylaminocarbonyl)isoxazol-5-yl, 3(ethylaminocarbonyl)isoxazol-5-yl, 3-(dimethylaminocarbonyl)isoxazol-5-yl, 3-(*iso*-propylaminocarbonyl)isoxazol-5-yl, 4-(methylaminocarbonyl)thiazol-2-yl, 4-(ethylaminocarbonyl)thiazol-2-yl, 4-(*iso*-propylaminocarbonyl)thiazol-2-yl, 4-(ethoxycarbonyl)thiazol-2-yl, 4-carboxythiazol-2-yl, 2-(methylaminocarbonyl)thiophen-5-yl, 2-(ethylaminocarbonyl)thiophen-5-yl, 2-(*iso*-propylaminocarbonyl)thiophen-4-yl, 2-(ethylaminocarbonyl)thiophen-4-yl, 2-(ethylaminocarbonyl)thiophen-4-yl, 2-(methoxycarbonyl)thiophen-4-yl, 2-(*iso*-propylaminocarbonyl)thiophen-4-yl, 2-(methoxycarbonyl)thiophen-4-yl, 2-carboxythiophen-4-yl, 2-(methoxycarbonyl)thiophen-5-yl, 2-carboxythiophen-5-yl, 3-(ethoxycarbonyl)furan-5-yl, 3-carboxyfuran-5-yl, benzofuran-3-yl, benzimidazol-2-yl, or 3-(1,3,4-oxadiazol-2-yl)furan-5-yl.

- 3. (Currently amended) A compound of formula (I) according to claim 1 or $\frac{1}{1}$ wherein $\frac{1}{1}$ and $\frac{1}{1}$ wherein $\frac{1}{1}$ are both hydrogen.
- 4. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein n is 0, 1, or 2.
- 5. (Original) A compound of formula (I) according to claim 4 wherein n is 1 or 2.
- 6. (Currently amended) A compound of formula (I) according to <u>claim 1</u> any one of the preceding claims wherein R³ and R⁴ are both hydrogen.
- 7. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein R² is phenyl substituted with chloro or fluoro, or R² is thiophenyl substituted with chloro.
- 8. (Original) A compound of formula (I) according to claim 7 wherein R² is 3-chloro-4-fluorophenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-chlorophenyl, 2-chlorothiophen-5-yl, or 4-fluorophenyl.
- 9. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein R⁷ is hydrogen or methyl.

- 10. (Original) A compound of formula (I) according to claim 9 wherein R⁷ is hydrogen.
- 11. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein R⁸ is hydrogen or methyl.
- 12. (Original) A compound of formula (I) according to claim 11 wherein R⁸ is hydrogen.
- 13. (Original) A compound of formula (I) according to claim 1 selected from the Examples.
- 14. -17. (Cancelled)
- 18. (Currently amended) A a-process for the preparation of a compound of formula (I) as defined in claim 1, which process comprises the reaction of a compound of formula (II) with a compound of formula (III);

wherein;

R¹, Y, R³, R⁴, R⁷, R⁸, and R² are as hereinbefore defined for formula (I) and U is a urea-forming group;

and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

- 19. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1 wherein R⁷ represents hydrogen, which process comprises the reaction of a compound of formula (IV) wherein R⁷ is hydrogen with a compound of formula R¹-Y-NCO wherein R¹ and Y are as hereinbefore defined and thereafter, if required, carrying out one or more of the following optional steps:
 - (i) converting a compound of formula (I) to a further compound of formula (I);
 - (ii) removing any necessary protecting group;
 - (iii) preparing a salt or solvate of the compound so formed.
- 20. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1 which process comprises the reaction of a compound of formula (IVM)

wherein R², R⁴, R⁷, and R⁸ are as hereinbefore defined and L¹ is a resin-bound leaving group, for example a polystyrene resin-bound, typically a Merrifield resin-bound, 4-thiophenoxy group, with a compound of formula (II) and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.
- 21. (Original) A compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.

- 22. (Currently amended) A compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, e.g. asthma or rhinitis.
- 23. (Currently amended) A method of manufacture of a medicament for the treatment of inflammatory conditions comprising including with said medicine Use of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.
- 24. (Currently amended) A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition e.g. asthma or rhinitis, which method comprises administering an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof.
- 25. (Original) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.
- 26. (Original) A compound selected from the list consisting of:
- [(2S)-4-(3-Chloro-4-fluoro-benzyl)morpholin-2-ylmethyl]carbamic acid tert-butyl ester;
- C-[(2S)-4-(3-Chloro-4-fluoro-benzyl)-morpholin-2-yl]-methylamine;
- [(2S)-4-(3-Chloro-4-fluoro-benzyl)morpholin-2-ylmethyl]carbamic acid 4-nitrophenyl ester;
- 1-(5-Chloromethyl-[1,3,4]oxadiazol-2-ylmethyl)-3-[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-ylmethyl]urea;
- {(2S)-4-[1-(3,4-Difluorophenyl)ethyl]morpholin-2-ylmethyl}carbamic acid 4-nitrophenyl ester;
- {(2S)-4-[1-(3,4-Difluorophenyl)ethyl]morpholin-2-ylmethyl}carbamic acid 4-nitrophenyl ester Isomer I;
- {(2S)-4-[1-(3,4-Difluorophenyl)ethyl]morpholin-2-ylmethyl}carbamic acid 4-nitrophenyl ester Isomer II;

- C-{(2S)-4-[1-(3,4-Difluorophenyl)ethyl]morpholin-2-yl}methylamine dihydrochloride;
- {(2S)-4-[1-(3,4-Difluoro-phenyl)-ethyl]-morpholin-2-ylmethyl}-carbamic acid tert-butyl ester;
- N'-(5-{3-[(2S)-4-(3,4-Dichloro-benzyl)morpholin-2-ylmethyl]ureidomethyl} furan-3-carbonyl)hydrazinecarboxylic acid tert-butyl ester;
- 1-[(2S)-4-(3,4-Dichloro-benzyl)morpholin-2-ylmethyl]-3-(4-hydrazinocarbonyl-furan-2-ylmethyl)urea hydrochloride,and;
- 1-[4-(N'-Formyl-hydrazinocarbonyl)furan-2-ylmethyl]-3-[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-ylmethyl]urea.
- 27. (Original) A compound selected from the list consisting of:
- 2-(5-Methyl-[1,3,4]oxadiazol-2-yl)ethylamine hydrochloride;
- 5-Aminomethyl-[1,3,4]oxadiazole-2-carboxylic acid methylamide hydrochloride;
- 2-Aminomethyloxazole-4-carboxylic acid methyl ester;
- 5-[(2,2,2-Trifluoro-acetylamino)methyl]furan-3-carboxylic acid methylamide;
- 5-Aminomethyl-furan-3-carboxylic acid methylamide;
- [3-(N'-Acetyl-hydrazino)-3-oxo-propyl]carbamic acid tert-butyl ester;
- [2-(5-Methyl-[1,3,4]oxadiazol-2-yl)ethyl]carbamic acid tert-butyl ester;
- 5-Aminomethylthiophene-3-carboxylic acid methylamide;
- 5-[(2,2,2-Trifluoroacetylamino)methyl]thiophene-3-carboxylic acid methylamide, and;
- (5-Methylcarbamoyl-[1,3,4]oxadiazol-2-ylmethyl)carbamic acid tert-butyl ester.